MOAI Consulting developed the AMPLIFY tool to estimate the clinical and humanistic benefits associated with pembrolizumab use across reimbursed indications in Portugal. Published in PharmacoEconomics – Open, the study estimated that, between 2017 and 2024, pembrolizumab treatment for 13,530 patients generated 14,042 additional quality-adjusted life years (QALYs), 17,914 additional life years, and 2,021 avoided deaths.